Acute Myocardial Infarction Market Size was Valued at USD 1,600 Million in 2024, Set for Strong Growth

The Acute Myocardial Infarction market size was valued ~USD 1,600 million in 2024 and is anticipated to grow with a significant CAGR during the study period (2020-2034). DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Acute Myocardial Infarction landscape.

Within the 7MM, the United States accounted for the largest market share in 2023, with an estimated value of around USD 1.2 billion. Among the emerging therapies, JARDIANCE and FARXIGA/FORXIGA are expected to play a major role in shaping the market over the forecast period.

In 2023, the United States recorded an estimated 822,800 new cases of Acute Myocardial Infarction (AMI), with the incidence expected to increase by 2034. During the same year, Japan reported roughly 45,700 cases of STEMI and about 34,500 cases of NSTEMI. Across the EU4 and the UK in 2023, AMI incidence was higher in males, with approximately 930,900 cases, compared with around 537,500 cases in females.

In 2023, the 7MM recorded approximately 1,500,000 new cases of Acute Myocardial Infarction (AMI), with the United States accounting for the largest share. Among these, NSTEMI cases outnumbered STEMI cases, with around 500,000 NSTEMI cases reported in the US. AMI was more common in men, who represented nearly 70% of new cases across the 7MM, compared with 30% in women. In total, the United States had an estimated 800,000 incident AMI cases in 2023.

This number is expected to increase by 2034 due to rising risk factors such as obesity and diabetes, sedentary lifestyles, unhealthy dietary habits, and improvements in medical diagnostics that allow earlier detection of heart conditions. In Japan, the pattern of AMI incidence differs from other regions; unlike the US and EU4/UK where NSTEMI cases are more common, STEMI cases outnumbered NSTEMI cases in Japan in 2023.

DelveInsight’s report  “Acute Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034”, provides a comprehensive analysis of the Acute Myocardial Infarction landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Acute Myocardial Infarction market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Acute Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acute Myocardial Infarction Market Forecast

Some of the key facts of the Acute Myocardial Infarction Market Report:

• Key Acute Myocardial Infarction Companies: AGEPHA Pharma, Genentech, Recardio, Regeneron/Sanofi, Amgen, Boehringer Ingelheim/Eli Lilly and Company, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Bayer, Novo Nordisk A/S, and others
• Key Acute Myocardial Infarction Therapies: LODOCO (colchicine), TNKase (tenecteplase), Dutogliptin, PRALUENT (alirocumab), REPATHA (evolocumab), JARDIANCE (empagliflozin), FDY-5301, Selatogrel, Asundexian, ZiltivekimabL, and others
• The Acute Myocardial Infarction market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Myocardial Infarction pipeline products will significantly revolutionize the Acute Myocardial Infarction market dynamics.

Acute Myocardial Infarction Overview

Acute Myocardial Infarction (AMI), commonly known as a heart attack, occurs when blood flow to a part of the heart muscle is suddenly blocked, usually by a blood clot in a coronary artery. This blockage causes damage or death of the heart muscle due to lack of oxygen. Symptoms often include chest pain or pressure, shortness of breath, nausea, and sweating. AMI is a medical emergency requiring immediate treatment to restore blood flow and prevent severe heart damage or death.

Get a Free sample for the Acute Myocardial Infarction Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/acute-myocardial-infarction-ami-market

Key Trends in Acute Myocardial Infarction Therapeutics Market:

• Advancement in Reperfusion Therapies: Continued innovation in thrombolytic agents, percutaneous coronary intervention (PCI) techniques, and adjunctive pharmacotherapies is improving outcomes and reducing mortality.
• Growth of Personalized and Precision Medicine: Increased use of genetic and biomarker profiling to tailor antiplatelet and antithrombotic therapies for individual patient risk profiles.
• Emergence of Next‑Generation Antithrombotic Agents: Development of novel anticoagulants and antiplatelet drugs with improved efficacy and reduced bleeding risk is reshaping treatment paradigms.
• Integration of Digital Health and Remote Monitoring: Use of wearable devices, telehealth, and mobile apps to monitor cardiac patients post‑AMI is enhancing follow‑up care and reducing readmissions.
• Focus on Early Diagnosis: Wider adoption of high‑sensitivity troponin tests and advanced imaging modalities is enabling quicker and more accurate detection of AMI, leading to timely treatment.

Acute Myocardial Infarction Epidemiology

The Acute Myocardial Infarction epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Acute Myocardial Infarction Epidemiology Segmentation:

The Acute Myocardial Infarction market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Incident Cases of AMI in the 7MM
• Type-specific Incidence of AMI in the 7MM
• Gender-specific Incidence of AMI the 7MM

Download the report to understand which factors are driving Acute Myocardial Infarction epidemiology trends @ Acute Myocardial Infarction Epidemiology Forecast

Recent Development In The Acute Myocardial Infarction Treatment Landscape:

• In January 2025, Bayer reported positive results for its menopause drug in a breast cancer study, indicating that elinzanetant could benefit a wider population of women experiencing vasomotor symptoms linked not only to menopause but also to a common breast cancer treatment.
• In February 2024, Indorsia announced that it has established a major global research and development partnership with Viatris for the worldwide development and commercialization of two Phase III assets, selatogrel and cenerimod. This collaboration includes an upfront payment of USD 350 million, along with potential payments for development and regulatory milestones, as well as contingent additional payments tied to sales milestones and tiered royalties ranging from mid-single-digit to low double-digit percentages on annual net sales.

Acute Myocardial Infarction Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Myocardial Infarction market or expected to get launched during the study period. The analysis covers Acute Myocardial Infarction market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Acute Myocardial Infarction Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Acute Myocardial Infarction Therapies and Key Companies

• LODOCO (colchicine): AGEPHA Pharma
• TNKase (tenecteplase): Genentech
• Dutogliptin: Recardio
• PRALUENT (alirocumab): Regeneron/Sanofi
• REPATHA (evolocumab): Amgen
• JARDIANCE (empagliflozin): Boehringer Ingelheim/Eli Lilly and Company
• FDY-5301: Faraday Pharmaceuticals
• JARDIANCE: Boehringer Ingelheim/Eli Lilly and Company
• Selatogrel: Idorsia Pharmaceuticals
• Asundexian: Bayer
• ZiltivekimabL: Novo Nordisk A/S

Discover more about therapies set to grab major Acute Myocardial Infarction market share @ Acute Myocardial Infarction Treatment Landscape

Acute Myocardial Infarction Market Drivers

• Rising Prevalence of Cardiovascular Diseases: Increasing cases of heart disease and associated risk factors such as hypertension, diabetes, and obesity are driving market demand.
• Advancements in Treatment Options: Development of novel therapies, including anticoagulants, thrombolytics, and interventional devices, is improving patient outcomes.
• Enhanced Diagnostic Capabilities: Improved imaging and biomarker-based diagnostics enable early detection and timely treatment of AMI.
• Growing Awareness and Screening: Increased public awareness and preventive cardiac programs contribute to higher diagnosis and treatment rates.
• Supportive Regulatory and Funding Environment: Government initiatives and funding for cardiovascular research promote innovation in AMI management.

Acute Myocardial Infarction Market Barriers

• High Treatment Costs: Expensive interventional procedures and long-term medications limit patient access, especially in low- and middle-income regions.
• Side Effects and Complications: Risk of bleeding, adverse drug reactions, and procedural complications can affect treatment adherence.
• Delayed Diagnosis: Non-specific symptoms and limited access to advanced diagnostics in some regions may delay timely intervention.
• Limited Availability of Advanced Therapies: Access to state-of-the-art interventional devices and therapies is uneven across geographies.
• Chronic Disease Burden: Patients often require long-term management for comorbidities, complicating care and impacting market growth.

Scope of the Acute Myocardial Infarction Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Acute Myocardial Infarction Companies: AGEPHA Pharma, Genentech, Recardio, Regeneron/Sanofi, Amgen, Boehringer Ingelheim/Eli Lilly and Company, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Bayer, Novo Nordisk A/S, and others
• Key Acute Myocardial Infarction Therapies: LODOCO (colchicine), TNKase (tenecteplase), Dutogliptin, PRALUENT (alirocumab), REPATHA (evolocumab), JARDIANCE (empagliflozin), FDY-5301, Selatogrel, Asundexian, ZiltivekimabL, and others
• Acute Myocardial Infarction Therapeutic Assessment: Acute Myocardial Infarction current marketed and Acute Myocardial Infarction emerging therapies
• Acute Myocardial Infarction Market Dynamics: Acute Myocardial Infarction market drivers and Acute Myocardial Infarction market barriers
• Acute Myocardial Infarction Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Acute Myocardial Infarction Unmet Needs, KOL’s views, Analyst’s views, Acute Myocardial Infarction Market Access and Reimbursement

To know more about Acute Myocardial Infarction companies working in the treatment market, visit @ Acute Myocardial Infarction Clinical Trials and Therapeutic Assessment

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.